AXL and renal cell carcinoma: Other clinical trials utilizing different potential target antigens including AXL receptor tyrosine kinase (AXL), receptor tyrosine kinase-like orphan receptor 2 (ROR2), EGFR and MSLN for RCC are currently ongoing.